U.S. Markets closed

CSL Limited (CSLLY)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
101.92-2.08 (-2.00%)
At close: 3:57PM EDT

CSL Limited

45 Poplar Road
Parkville, VIC 3052
Australia
61 3 9389 1911
http://www.csl.com.au

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees27,000

Key Executives

NameTitlePayExercisedYear Born
Mr. Paul R. Perreault B.A.MD, CEO & Exec. Director4.23MN/A1957
Dr. Paul F. McKenzieChief Operating Officer2.74MN/A1966
Dr. Robert Andrew Cuthbertson A.O., BMedSci, MBBS, Ph.D., FTSE, FAHMS, AOSr. Adviser & Exec. Director1.48MN/A1955
Ms. Joy Carolyn Linton B.Com., BComm, Grad Dip AFI, GAICDChief Financial OfficerN/AN/A1965
Mr. Mark DehringHead of Investor RelationsN/AN/AN/A
Mr. Gregory Boss B.S., BS(Hons), J.D.Exec. VP of Legal & Group Gen. CounselN/AN/A1961
Christina HickieSr. Mang. of CommunicationsN/AN/AN/A
Ms. Elizabeth Walker B.A., M.S.Exec. VP & Chief HR OfficerN/AN/A1970
Dr. Karen EtchbergerExec. VP of Quality & Bus. ServicesN/AN/A1958
Ms. Sharon McHaleHead of Public AffairsN/AN/AN/A
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through two segments, CSL Behring and Seqirus. The CSL Behring segment offers plasma therapies for the treatment of immunodeficiency, bleeding disorders, hereditary angioedema, Alpha-1 antitrypsin deficiency, and neurological disorders. This segment also conducts research on plasma and non-plasma therapies; and receives license and royalty from the commercialization of intellectual property. The Seqirus segment manufactures and distributes non-plasma biotherapeutic products; and develops influenza vaccines. CSL Limited was founded in 1916 and is headquartered in Parkville, Australia.

Corporate Governance

CSL Limited’s ISS Governance QualityScore as of April 1, 2021 is 1. The pillar scores are Audit: 3; Board: 1; Shareholder Rights: 1; Compensation: 1.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.